Literature DB >> 27427530

Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.

Andrea S Wolf1, Raja M Flores2.   

Abstract

The role of surgical resection in malignant pleural mesothelioma (MPM) is based on the principle of macroscopic resection of a solid tumor with adjuvant therapy to treat micrometastatic disease. Extrapleural pneumonectomy (EPP) and pleurectomy decortication (P/D) have been developed in this context. Cancer-directed surgery for MPM is associated with a 5-year survival rate of 15%. Evidence indicates that P/D is better tolerated by patients and suggests survival is no worse when compared with EPP. Although EPP is still performed in highly selected cases, the authors advocate radical P/D whenever possible for patients with MPM.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extrapleural pneumonectomy; Malignant pleural mesothelioma; Pleurectomy decortication

Mesh:

Year:  2016        PMID: 27427530     DOI: 10.1016/j.thorsurg.2016.04.003

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  13 in total

Review 1.  Overview of treatment related complications in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

2.  Biomarkers in malignant mesothelioma-an unfulfilled need or a waste of resources?

Authors:  Robin Cornelissen; Joachim G J V Aerts
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 3.  Extended pleurectomy decortication: the current role.

Authors:  Rocco Bilancia; Marco Nardini; David A Waller
Journal:  Transl Lung Cancer Res       Date:  2018-10

4.  Pleurectomy/decortication versus extrapleural pneumonectomy: a critical choice.

Authors:  Pier Luigi Filosso; Francesco Guerrera; Paolo Olivo Lausi; Roberto Giobbe; Paraskevas Lyberis; Enrico Ruffini; Alberto Oliaro
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.

Authors:  Hugh S Elliott; Ur Metser; Marc de Perrot; John Cho; Penelope Bradbury; Patrick Veit-Haibach; Douglas Hussey; Tau Noam
Journal:  Br J Radiol       Date:  2018-03-29       Impact factor: 3.039

Review 6.  Immunotherapy and radiation therapy for malignant pleural mesothelioma.

Authors:  Evan W Alley; Sharyn I Katz; Keith A Cengel; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2017-04

7.  A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication.

Authors:  Jarrod D Predina; Andrew D Newton; Christopher Corbett; Leilei Xia; Michael Shin; Lydia Frenzel Sulfyok; Olugbenga T Okusanya; Keith A Cengel; Andrew Haas; Leslie Litzky; John C Kucharczuk; Sunil Singhal
Journal:  Ann Thorac Surg       Date:  2018-07-17       Impact factor: 4.330

Review 8.  Surgery for malignant pleural mesothelioma: an international guidelines review.

Authors:  Sara Ricciardi; Giuseppe Cardillo; Carmelina Cristina Zirafa; Francesco Carleo; Francesco Facciolo; Gabriella Fontanini; Luciano Mutti; Franca Melfi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  Long-term outcomes after lung-sparing surgery for epithelial mesothelioma.

Authors:  Cristiano Breda; Simone Furia; Giuseppe Lucchini; Antonio Zaccaria; Enrico Verderi; Giuseppe Natale; Fabio Lo Giudice; Roberta Cavallin; Andrea Ferronato; Paolo Fontana
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

10.  Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.

Authors:  Jun Hyeok Lim; Joon Young Choi; Yunjoo Im; Hongseok Yoo; Byung Woo Jhun; Byeong-Ho Jeong; Hye Yun Park; Kyungjong Lee; Hojoong Kim; O Jung Kwon; Joungho Han; Myung-Ju Ahn; Jhingook Kim; Sang-Won Um
Journal:  PLoS One       Date:  2020-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.